Theravance ends R&D, lays off 50% of workers after Phase 3 fail
Theravance终止研发，三期试验失败后裁员50%

Theravance Biopharma will wind down its entire R&D organization and lay off 50% of its overall workforce after another Phase 3 fail for an experimental medicine called ampreloxetine.
在名为ampreloxetine的实验性药物再次在三期临床试验中失败后，Theravance Biopharma将关闭其整个研发组织，并裁减其整体员工的50%。